NIH Research Matters
May 6, 2013
Killing Cancer With Radioactive Bacteria
Live bacteria delivered a lethal radioactive payload to pancreatic cancer cells in mice. With further development, the experimental approach might one day help doctors fight this deadly type of cancer in people.
Experts predict more than 45,000 new cases of pancreatic cancer will arise nationwide this year, with over 38,000 deaths from the disease. Cancer therapy is often effective against primary tumors, but not against metastases—cancer cells that spread to other parts of the body. Unfortunately, most diagnoses are made after pancreatic cancer has spread.
Pancreatic tumors force immune cells to tolerate and even support their growth. To take advantage of this property, a research team led by Drs. Ekaterina Dadachova and Claudia Gravekamp at Albert Einstein College of Medicine of Yeshiva University used the bacterium Listeria monocytogenes, which is known for causing foodborne illness. In previous work, the scientists showed that weakened Listeria injected into mice persisted in primary tumors and metastases but were cleared from normal tissues by the immune system within 3 to 5 days. The bacteria might therefore be used to deliver anticancer agents to kill tumor cells.
In their new study, the researchers coupled a radioisotope, 188rhenium, to the bacteria by using Listeria-binding antibodies. The researchers chose rhenium because it delivers a short, strong dose of deadly beta-particles but has a half-life of less than 17 hours. The work was funded by NIH’s National Cancer Institute (NCI) and National Institute on Aging (NIA). Results appeared online on April 22, 2013, in the Proceedings of the National Academy of Sciences.
The researchers first confirmed that the radioactive bacteria could infect and kill tumor cells from a mouse model of aggressive pancreatic cancer. They then developed a protocol to maintain high enough bacterial levels in the mouse body to kill tumor cells without making the mice sick from infection. The protocol involved multiple injections with small doses of the bacteria over the course of 3 weeks.
The scientists found that this treatment reduced the number of metastases by 90% compared to control mice injected with saline. It also reduced primary tumor weight by an average of 64% compared to saline controls.
Metastases had radioactivity levels 4- to 15-fold higher than all organs except the liver and kidneys. Levels in livers and kidneys were comparable to those in metastases. However, the radioactivity didn’t appear to damage or alter the organs’ functions. The normal cells in these tissues may not be as vulnerable to radioactive damage as those in tumors because they don’t divide as quickly. Neither the bacteria nor radioactivity were detected in any normal or tumor tissue a week after the last treatment.
This approach might lead to novel therapies to combat metastases and help prevent pancreatic cancer from recurring. “At this point, we can say that we have a therapy that is very effective for reducing metastasis in mice,” Gravekamp says. “Our goal is to clear 100% of the metastases, because every cancer cell that stays behind can potentially form new tumors.”—by Harrison Wein, Ph.D.
- Breaking Down Pancreatic Tumor Defenses:
- Pancreatic Cancer:
- Targeted Light Therapy Destroys Cancer Cells:
Reference: Proc Natl Acad Sci U S A. 2013 Apr 22. [Epub ahead of print]. PMID: 23610422.
Funding: NIH’s National Cancer Institute (NCI) and National Institute on Aging (NIA).
NIH Research Matters
Bldg. 31, Rm. 5B64A, MSC 2094
Bethesda, MD 20892-2094
About NIH Research Matters
Editor: Harrison Wein, Ph.D.
Assistant Editors: Vicki Contie, Carol Torgan, Ph.D.
NIH Research Matters is a weekly update of NIH research highlights from the Office of Communications and Public Liaison, Office of the Director, National Institutes of Health.